

Update on the Diagnosis and Treatment of Coronary Heart Disease

This supplement to *The American Journal of Managed Care* addresses the management of patients at risk for coronary heart disease, including low-density lipoprotein cholesterol reduction and goal attainment. Practice patterns are discussed here, including the implications of switching therapies to attain target goals.

■ Faculty

Nze Anoka, MS, MBA

Statistical Programmer
AstraZeneca Pharmaceuticals, LP
Wilmington, Delaware

Michael F. Bullano, PharmD

Associate Director
Health Economics and Outcomes Research
AstraZeneca Pharmaceuticals, LP
Wilmington, Delaware

Michael H. Davidson, MD, FACC, FACP

Clinical Professor of Medicine
Director of Preventive Cardiology
The University of Chicago, Pritzker School of Medicine
Executive Medical Director
Radiant Research
Chicago, Illinois

Kathleen M. Fox, PhD

Adjunct Assistant Professor
Department of Epidemiology & Preventive Medicine
University of Maryland School of Medicine
Baltimore, Maryland

Sanjay K. Gandhi, PhD

Director
Health Economics and Outcomes Research
AstraZeneca Pharmaceuticals LP
Wilmington, Delaware

Caroline R. Harley, PhD

Vice President
Health Economics & Outcomes
i3 Innovus
Eden Prairie, Minnesota

James M. McKenney, PharmD

Professor Emeritus
Virginia Commonwealth University
President and Chief Executive Officer
National Clinical Research, Inc
Richmond, Virginia

Robert L. Ohsfeldt, PhD

Professor
Texas A&M Health Science Center
Department of Health Policy & Management
College Station, Texas

■ Faculty Disclosures

These participants report relationships with the following pharmaceutical companies:

Nze Anoka, MS, MBA

Employee of:
AstraZeneca

Michael F. Bullano, PharmD

Employee of:
AstraZeneca

Michael H. Davidson, MD, FACC, FACP

Consultant to:
Abbott Laboratories
AstraZeneca
Daiichi-Sankyo, Inc
Merck & Co, Inc
Merck/Schering-Plough
Pfizer Inc
Reliant Pharmaceuticals, Inc
Roche Pharmaceuticals
sanofi-aventis
Takeda Pharmaceuticals

Grant support from:
Abbott Laboratories
AstraZeneca
Daiichi-Sankyo, Inc
Merck & Co, Inc
Merck/Schering-Plough
Pfizer Inc
Reliant Pharmaceuticals, Inc
Roche Pharmaceuticals
Takeda Pharmaceuticals

Speaker's bureau of:
Abbott Laboratories
AstraZeneca
Daiichi-Sankyo, Inc
Merck & Co, Inc
Merck/Schering-Plough
Pfizer Inc
Reliant Pharmaceuticals, Inc
Takeda Pharmaceuticals

Kathleen M. Fox, PhD

Consultant to:
AstraZeneca

Sanjay K. Gandhi, PhD

Employee of:
AstraZeneca

Caroline R. Harley, PhD

Grant support from:
AstraZeneca

James M. McKenney, PharmD

Honorarium from:
AstraZeneca

Grant support from:
Abbott Laboratories
Aegerion
Akros
AstraZeneca
GSK
KOS
Merck/Schering-Plough
Microbia
Pfizer Inc
Roche
Takeda

Consultant to:
Abbott
Aegerion
Merck
Sankyo

Robert L. Ohsfeldt, PhD

Grant support from:
AstraZeneca

It is the policy of *The American Journal of Managed Care* to have all faculty who participate in programs sponsored by pharmaceutical companies disclose any real or apparent conflicts of interest.

We would like to thank **Chris Conner, PharmD**, for his editorial assistance in the development of the first article (as noted in the footnote).

Signed disclosures are on file at the office of *The American Journal of Managed Care*, Princeton, New Jersey.

Update on the Diagnosis and Treatment of Coronary Heart Disease

This publication was made possible by a grant from **AstraZeneca**.



The contents of this supplement may include information regarding the use of products that may be inconsistent outside the approved labeling for these products in the United States. Physicians should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.